Tag
The discontinuation of Biogen’s Aduhelm is a cautionary tale of overpromising, under-delivering, and an inside look at FDA sausage-making.

This is part 2 of a package on sponsored disease awareness campaigns and other controversial drug marketing practices, focusing on…

New marketing campaigns about forgetfulness and distraction could lead people to seek the costly Aduhelm drug for Alzheimer’s disease even…
